Literature DB >> 19228926

Nf1 haploinsufficiency and Icsbp deficiency synergize in the development of leukemias.

Jessica Koenigsmann1, Cornelia Rudolph, Sandrine Sander, Olivia Kershaw, Achim D Gruber, Lars Bullinger, Brigitte Schlegelberger, Dirk Carstanjen.   

Abstract

Loss of neurofibromin or interferon consensus sequence binding protein (Icsbp) leads to a myeloproliferative disorder. Transcription of NF1 is directly controlled by ICSBP. It has been postulated that loss of NF1 expression resulting from loss of transcriptional activation by ICSBP contributes to human hematologic malignancies. To investigate the functional cooperation of these 2 proteins, we have established Icsbp-deficient mice with Nf1 haploinsufficiency. We here demonstrate that loss of Icsbp and Nf1 haploinsufficiency synergize to induce a forced myeloproliferation in Icsbp-deficient mice because of an expansion of a mature myeloid progenitor cell. Furthermore, Nf1 haploinsufficiency and loss of Icsbp contribute synergistically to progression of the myeloproliferative disorder toward transplantable leukemias. Leukemias are characterized by distinct phenotypes, which correlate with progressive genetic abnormalities. Loss of Nf1 heterozygosity is not mandatory for disease progression, but its occurrence with other genetic abnormalities indicates progressive genetic alterations in a defined subset of leukemias. These data show that loss of the 2 tumor suppressor genes Nf1 and Icsbp synergize in the induction of leukemias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228926     DOI: 10.1182/blood-2008-05-158485

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Interferon regulatory factor-8-driven myeloid differentiation is regulated by 12/15-lipoxygenase-mediated redox signaling.

Authors:  Michelle Kinder; James E Thompson; Cong Wei; Suresh G Shelat; Ian A Blair; Martin Carroll; Ellen Puré
Journal:  Exp Hematol       Date:  2010-07-18       Impact factor: 3.084

Review 2.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.

Authors:  Jeremy D Waight; Debarati Banik; Elizabeth A Griffiths; Michael J Nemeth; Scott I Abrams
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

4.  Cutting edge: IRF8 regulates Bax transcription in vivo in primary myeloid cells.

Authors:  Jine Yang; Xiaolin Hu; Mary Zimmerman; Christina M Torres; Dafeng Yang; Sylvia B Smith; Kebin Liu
Journal:  J Immunol       Date:  2011-09-26       Impact factor: 5.422

5.  IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia.

Authors:  Xiaolin Hu; Dafeng Yang; Mary Zimmerman; Feiyan Liu; Jine Yang; Swati Kannan; Andreas Burchert; Zdzislaw Szulc; Alicja Bielawska; Keiko Ozato; Kapil Bhalla; Kebin Liu
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

6.  Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.

Authors:  Seung-Hee Jo; Jonathan H Schatz; Jaime Acquaviva; Harinder Singh; Ruibao Ren
Journal:  Blood       Date:  2010-06-28       Impact factor: 22.113

7.  The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.

Authors:  Colleen S Netherby; Michelle N Messmer; Lauren Burkard-Mandel; Sean Colligan; Austin Miller; Eduardo Cortes Gomez; Jianmin Wang; Michael J Nemeth; Scott I Abrams
Journal:  J Immunol       Date:  2017-03-29       Impact factor: 5.422

Review 8.  Molecular control of monocyte development.

Authors:  Rachael L Terry; Stephen D Miller
Journal:  Cell Immunol       Date:  2014-03-12       Impact factor: 4.868

9.  Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity.

Authors:  Debarati Banik; A Nazmul H Khan; Even Walseng; Brahm H Segal; Scott I Abrams
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

10.  Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.

Authors:  Sibylle Cocciardi; Anna Dolnik; Silke Kapp-Schwoerer; Frank G Rücker; Susanne Lux; Tamara J Blätte; Sabrina Skambraks; Jan Krönke; Florian H Heidel; Tina M Schnöder; Andrea Corbacioglu; Verena I Gaidzik; Peter Paschka; Veronica Teleanu; Gudrun Göhring; Felicitas Thol; Michael Heuser; Arnold Ganser; Daniela Weber; Eric Sträng; Hans A Kestler; Hartmut Döhner; Lars Bullinger; Konstanze Döhner
Journal:  Nat Commun       Date:  2019-05-02       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.